The traditional “bottom-up” approach to drug discovery is not best equipped to translate these unprecedented insights into the next wave of new medicines.
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages evolutionary insights from fungi to unearth next-generation precision medicines.
Through our data-immersive and technologically expansive discovery engine, we are bringing sophisticated medicines to patients in urgent need of breakthrough disease intervention.
We are uniquely positioned to discover mechanistically and structurally novel precision medicines against high-impact disease targets faster than ever before. LifeMine’s lead clinical-stage program, LIFE-001, is a precision-engineered calcineurin inhibitor being developed for multiple immune-mediated disease indications and organ transplant rejection.
Backed by leading life sciences investors, LifeMine is a fast-growing company. We are looking for top talent who share in our passion for groundbreaking science and commitment to advancing next-generation precision medicines.
LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation
Genomic Discovery and Structure–Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase Inhibitors
Greg Verdine: What is LifeMine’s Mission?
For biotech entrepreneur Greg Verdine, opportunity just kept knocking
